Galanthamine, the most relevant one, has been commercialized for the palliative treatment of Alzheimer’s disease symptoms since 2001 due to its potential as an acetylcholinesterase (AChE) inhibitor. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.